<DOC>
	<DOCNO>NCT01173926</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare blood glucose-lowering effect NN5401 ( insulin degludec/insulin aspart , IDegAsp ) NN1250 ( insulin degludec , IDeg ) insulin aspart ( IAsp ) subject type 1 diabetes mellitus .</brief_summary>
	<brief_title>Comparison Effect NN5401 With Effect NN1250 Insulin Aspart Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) least 12 month . Body mass index 18.028.0 kg/m^2 ( inclusive ) Subject donate blood plasma past month 500 mL within 3 month prior screen Smoker ( define subject smoke 5 cigarette equivalent per day ) . Not able willing refrain smoking use nicotine gum transdermal nicotine patch inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>